Archives2023202220212020201920182017201620152014201320122011 May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More May 11, 2023TR1 Lanstead holding 10 May 2023 Read More May 11, 2023FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022 Read More April 19, 2023FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus Read More April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More February 06, 2023Phase 2/3 adaptive study design for Lupus study agreed with Avion Read More January 05, 2023Major Interest | TR1 | Gary Smith Read More January 03, 2023Major Interest | TR1 | Lanstead Capital – 3 January 2023 Read More December 22, 2022Grant of Share Options Read More December 22, 2022End of Year Update Read More 1234…20
May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More
April 19, 2023FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus Read More
April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More
March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More
March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More
